Document is current

Article History

Received: 25 July 2025

Accepted: 28 October 2025

First Online: 21 November 2025

Declarations

:

: Eléonore Maury and Mieke Jansen are employees of the sponsor. Ann Belmans and Kris Bogaerts were paid by the sponsor via their institution to perform the analyses. Lorenz Van der Linden has no conflicts of interest that are directly relevant to the content of this article.

: This secondary analysis of pseudonymized data was conducted in accordance with applicable regulations and approved by the Belgian Data Protection Authority. The need for informed consent was waived under national guidelines. All the protocols including the collection of data complied with the European General Data Protection Regulations. The purpose of this study and data processing were detailed in a privacy notice made available to the healthcare professional community in Belgium, aimed at informing patients treated with sacubitril/valsartan, per request of the Belgian Data Protection Authority.

: Not applicable.

: Not applicable.

: Additional information is available from the corresponding author (eleonore.maury@novartis.com) upon reasonable request. The information presented in this paper combines several Belgian administrative databases. The data use is subject to the European Union’s General Data Protection Regulation. Patient-level data were available via the healthdata.be in the framework of a managed entry agreement between Novartis and the payer institute National Institute for Health and Disability Insurance (NIHDI-RIZIV-INAMI). Access to data was restricted to address uncertainties in the context of a managed entry agreement and related publication. Patient-level data may not be shared publicly or transferred because of ethical reasons and security considerations.

: Not applicable.

: Concept: MJ, LV. Conduct: EM, MJ. Interpretation: EM, LV, MJ, AB, KB. Writing: LV and EM drafted the manuscript, reviewed and edited by EM, LV, MJ, AB, KB.